Corporate ActionMay 13, 2026, 04:18 PM
Altimmune Raises $211.2M in Offering; Q1 Net Loss $(22.6)M
AI Summary
Altimmune, Inc. reported a net loss of $(22.6) million for the first quarter of 2026, an increase from $(19.6) million in Q1 2025, driven by higher operating expenses. Subsequent to the quarter, the company completed an April 2026 Offering, raising approximately $211.2 million in net proceeds and potentially an additional $225 million from warrant exercises. The company also increased its authorized common stock from 200 million to 400 million shares to support future capital needs.
Key Highlights
- Raised $211.2 million net proceeds from April 2026 Offering.
- Potential $225 million additional gross proceeds from warrants in April 2026 Offering.
- Q1 2026 net loss was $(22.6) million, compared to $(19.6) million in Q1 2025.
- Research and development expenses increased to $16.2 million in Q1 2026.
- General and administrative expenses rose to $8.1 million in Q1 2026.
- Cash, cash equivalents, and restricted cash totaled $97.6 million as of March 31, 2026.
- Authorized common stock increased from 200 million to 400 million shares.
Price Impact
More from ALT